Subscribe to Search results

There were cost pressures related to heat-treated factor product.

Published on:

Professor Bloom stated that, "A small percentage of these freeze dried preparations contain, unavoidably, the virus of serum hepatitis and therefore potentially dangerous to the patient."

Published on:

Dr Jones "had his wrists slapped for public statements" by the CMO, Dr Donald Acheson.

Published on:

There was some evidence that some of this stock of NHS products made from unscreened donations was destroyed.

Published on:

The UK lacked the ease of access to laboratory screening to check on viral inactivation.

Published on:

There was some resistance by some clinicians to the use of heat-treated product.

Published on:

Earlier availability of virally inactivated concentrates would have made the biggest difference.

Published on:

Some Factor 8 product had been recalled, but this was probably a batch recall rather than a general recall.

Published on:

Dr Milton Mozen, the director of biochemical research and development at Cutter, emphasised in his evidence to the Institute of Medicine in the US that a heat treatment process is successful as applied by one manufacturer, it does not follow that this process would be applicable to the unique products of the other manufacturer.

Published on:

Dr Peter Fernandes stated that similar stabilisers to those which worked with the globulin could work with antihemophilic factor.

Published on:

Clive Collins stated that ,"Given the specialised medical nature of the seroconversion problem it was appropriate that my Medical Department colleagues dealt directly with the DHSS Medical staff."

Published on:

Dr Shanbrom had suggested to the executives that they should no longer take plasma from hepatitis hotspots such as downtown Los Angeles and from prisons because of the risks.

Published on:

J K Smith, Lowell Winkelman and P A Feldman reported the interim results that severe heating had been more effective in preventing transmission of non-A non-B Hepatitis than the milder heating given to at least two US commercial products.

Published on:

A clinical trial of 8Y was reported to be at a stage where several patients had safely passed the point at which first evidence of non-A non-B Hepatitis transmission would have been expected.

Published on:

Milt Mozen visited SNBTS PFC and discussed the issue of hepatitis with Jim Smith.

Published on:

A H Woodhead wrote to all Blood Transfusion Service directors about a batch of Factorate recalled by Armour Pharmaceuticals.

Published on:

The Committee on Safety of Medicines reviewed Dr Peter Jones' letter regarding AIDS and the heat treatment of clotting factor and advised that there was insufficient evidence for action to be taken on any specific product.

Published on:

Dr Jones apologised to the DHSS for making public his statement about heat-treated Factor 8 being unsafe.

Published on:

The CBLA agreed to finance the trial of 8CRV.

Published on:

The Krever Inquiry found that Armour should have informed the Canadian Bureau of Biologics about Dr Prince's findings, but chose not to.

Published on: